Cargando…
Successful Proof-of-Concept for Topical Delivery of Novel Peptide ALM201 with Potential Usefulness for Treating Neovascular Eye Disorders
PURPOSE: To evaluate the therapeutic benefit of a novel peptide, ALM201, in ocular pathologic vascularization. DESIGN: Experimental study in mouse, rat, and rabbit animal models. PARTICIPANTS: Ten-week-old Lister Hooded male rats, 8-week-old Brown Norway male rats, 9-day-old C57BL/6J mice, and 12-mo...
Autores principales: | Obasanmi, Gideon, Nesbit, M. Andrew, Cobice, Diego, Mackay, Logan, McGimpsey, Stuart, Wappett, Mark, Cranston, Aaron N., Moore, Tara C.B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9560569/ https://www.ncbi.nlm.nih.gov/pubmed/36249680 http://dx.doi.org/10.1016/j.xops.2022.100150 |
Ejemplares similares
-
FKBPL-based peptide, ALM201, targets angiogenesis and cancer stem cells in ovarian cancer
por: Annett, Stephanie, et al.
Publicado: (2019) -
In vitro proof of concept studies of radiotoxicity from Auger electron-emitter thallium-201
por: Osytek, Katarzyna M., et al.
Publicado: (2021) -
Not Alms, but a Friend
Publicado: (1887) -
A first-in-human Phase I dose-escalation trial of the novel therapeutic peptide, ALM201, demonstrates a favourable safety profile in unselected patients with ovarian cancer and other advanced solid tumours
por: El Helali, Aya, et al.
Publicado: (2022) -
Baltimore Alms-House Infirmary
Publicado: (1830)